Principal Financial Group Inc. Acquires 11,156 Shares of Corcept Therapeutics Incorporated $CORT

Posted by Geri Gentry on Jul 23rd, 2026

Principal Financial Group Inc. grew its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Free Report) by 2.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 455,248 shares of the biotechnology company’s stock after acquiring an additional 11,156 shares during the period. Principal Financial Group Inc.’s holdings in Corcept Therapeutics were worth $18,351,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in CORT. Advisory Services Network LLC bought a new stake in shares of Corcept Therapeutics during the third quarter valued at about $25,000. Larson Financial Group LLC grew its stake in Corcept Therapeutics by 2,326.3% during the third quarter. Larson Financial Group LLC now owns 461 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 442 shares in the last quarter. Gould Capital LLC increased its holdings in Corcept Therapeutics by 50.0% during the 3rd quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 200 shares during the period. Torren Management LLC purchased a new stake in Corcept Therapeutics in the 4th quarter worth approximately $25,000. Finally, CIBC Private Wealth Group LLC lifted its stake in Corcept Therapeutics by 128.5% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 770 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 433 shares in the last quarter. 93.61% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Piper Sandler boosted their price target on shares of Corcept Therapeutics from $73.00 to $88.00 and gave the company an “overweight” rating in a research report on Friday, May 1st. UBS Group set a $135.00 price objective on Corcept Therapeutics in a research note on Thursday, May 28th. Zacks Research upgraded Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, May 4th. Weiss Ratings restated a “hold (c-)” rating on shares of Corcept Therapeutics in a research note on Wednesday, June 24th. Finally, Truist Financial raised Corcept Therapeutics to a “strong-buy” rating in a report on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Corcept Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $88.83.

Check Out Our Latest Analysis on CORT

Insider Transactions at Corcept Therapeutics

In other news, Director James N. Wilson sold 10,000 shares of the company’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $83.20, for a total value of $832,000.00. Following the completion of the sale, the director owned 1,094,543 shares of the company’s stock, valued at approximately $91,065,977.60. This represents a 0.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Sean Maduck sold 25,000 shares of Corcept Therapeutics stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $88.35, for a total transaction of $2,208,750.00. Following the completion of the transaction, the insider owned 9,755 shares in the company, valued at approximately $861,854.25. The trade was a 71.93% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 300,000 shares of company stock worth $22,088,050. Corporate insiders own 20.70% of the company’s stock.

Corcept Therapeutics Trading Down 5.0%

Shares of NASDAQ CORT opened at $90.88 on Thursday. The stock has a market cap of $9.76 billion, a price-to-earnings ratio of 259.66 and a beta of 0.47. Corcept Therapeutics Incorporated has a 1-year low of $28.66 and a 1-year high of $95.79. The stock’s 50-day moving average is $78.85 and its 200 day moving average is $53.77.

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last issued its earnings results on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.19). Corcept Therapeutics had a return on equity of 7.40% and a net margin of 6.14%.The firm had revenue of $164.90 million during the quarter, compared to analysts’ expectations of $185.83 million. During the same period in the prior year, the company earned $0.17 EPS. The firm’s quarterly revenue was up 4.9% compared to the same quarter last year. On average, analysts forecast that Corcept Therapeutics Incorporated will post 0.53 EPS for the current fiscal year.

Corcept Therapeutics Profile

(Free Report)

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.